World Library  
Flag as Inappropriate
Email this Article

Miglustat

Article Id: WHEBN0012428263
Reproduction Date:

Title: Miglustat  
Author: World Heritage Encyclopedia
Language: English
Subject: Imiglucerase, Actelion, Taliglucerase alfa, Male contraceptive, Genetic disorder
Collection: Iminosugars, Orphan Drugs, Piperidines, Transferase Inhibitors
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Miglustat

Miglustat
Systematic (IUPAC) name
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Clinical data
AHFS/Drugs.com
MedlinePlus
Licence data US FDA:
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Bioavailability 97%
Protein binding Nil
Metabolism Nil
Half-life 6–7 hours
Excretion Renal, unchanged
Identifiers
CAS number  YesY
ATC code A16
PubChem
DrugBank
ChemSpider  YesY
UNII  YesY
ChEBI  YesY
ChEMBL  YesY
Synonyms 1,5-(butylimino)-1,5-dideoxy-D-glucitol, N-butyl-deoxynojirimycin
Chemical data
Formula C10H21NO4 
Mol. mass 219.28 g/mol
 YesY   

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I Gaucher disease (GD1). It is marketed under the trade name Zavesca.

Contents

  • Medical uses 1
  • Contraindications 2
  • Adverse effects 3
  • Mechanism of action 4
  • Physical and chemical properties 5
  • Research 6
  • See also 7
  • References 8

Medical uses

Miglustat is used to treat adults with mild-to-moderate type I Gaucher disease for whom enzyme replacement therapy is unsuitable.[1] It was approved in Europe in 2002[2] and by the US FDA in 2003.[3]

Miglustat is the first treatment to be approved for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC); it has been approved in Europe in 2009, Canada in 2010, and Japan in 2012, but not in the US where the FDA declined to approve it in 2010 and called for more data.[4][5][6][7]

Contraindications

Miglustat is contraindicated for people with neurological conditions, kidney problems, women who are pregnant, and men and women planning to conceive a child.[8]

Adverse effects

Serious side effects include pain, burning, numbness or tingling in the hands, arms, legs, or feet; shaking hands that cannot be controlled; changes in vision; and easy bruising or bleeding. Common side effects include gastrointestinal effects (including diarrhea, stomach pain or bloating, gas, loss of appetite, weight loss, upset stomach, vomiting, constipation), dry mouth, muscular effects (including weakness, muscle cramps, especially in the legs, feeling of heaviness in the arms or legs, unsteadiness when walking), back pain, dizziness, nervousness, headache, memory problems, and difficult or irregular menstruation (period).[8]

Mechanism of action

Type I Gaucher's disease is an autosomal recessive disorder; parents are generally healthy carriers with one functional and one mutated (nonfunctioning) copy of the Gaucher disease gene, GBA. People with type I Gaucher have a defect in the enzyme called glucocerebrosidase (also known as acid β-glucosidase). Glucocerebrosidase is an enzyme, and its function is to destroy glucocerebroside (also known as glucosylceramide). When this enzyme doesn't work, glucocerebroside accumulates, which in turn causes liver and spleen enlargement, changes in the bone marrow and blood, and bone disease.[9]

Other treatments on the market (Imiglucerase (approved in 1995)[10] Velaglucerase (approved in 2010),[11] Taliglucerase alfa (Elelyso) (approved in 2012) [12]) are enzyme replacement therapy - they are functioning versions of the enzyme doesn't work. Migulstat works differently - it prevents the formation of the substance that builds up when the enzyme doesn't work; this is called substrate reduction therapy.[13]

Physical and chemical properties

Miglustat is an iminosugar, a synthetic analogue of D-glucose[14] and a white to off-white crystalline solid that has a bitter taste.[15]

Research

In July 2004 Actelion started a clinical trial of miglustat to treat Tay–Sachs disease, particularly late-onset Tay–Sachs with an estimated enrollment of 10 subjects; the trial ended August 2007.[16]

In November 2007, Actelion initiated a clinical trial with miglustat in people with cystic fibrosis (CF) who have the ΔF508 in both copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene; the study ended in March 2008.[17] The cystic fibrosis trial showed no effect.[18]

See also

  • Miglitol, an oral antidiabetic drug with a similar structure

References

  1. ^ Cox TM et al.: Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513-26. PMID 14605497
  2. ^ European Medicines Agency. Human Medicines Database. Zavesca (miglustat) Page Accessed 1 September 2014.
  3. ^ Actelion Press Release August 2003. Zavesca approved -- first oral treatment option for type 1 Gaucher disease
  4. ^ UK Medicines Information. New Drugs Online Report for miglustat
  5. ^ Staff, The Pharma Letter. 4 April 2012. Actelion drops setipiprant, gets miglustat approval in Japan
  6. ^ Kevin Grogan for PharmaTimes. 10 March 2010. FDA rejects Actelion's Zavesca for rare NP-C disease
  7. ^ Actelion Press Release. 23 March 2010 Zavesca® (Miglustat) First Treatment Available in Canada for Rare Progressive Niemann-Pick Type C Disease
  8. ^ a b American Society of Health-System Pharmacists, Inc. for the Public Library of Medicine. Miglustat on MedlinePlus Accessed 1 September 2014
  9. ^ Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012;2012:13-8. doi: 10.1182/asheducation-2012.1.13. PMID 23233555 (free full text)
  10. ^ Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. PMID 22563238 (free full text)
  11. ^ "Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type I Gaucher Disease". Medicalnewstoday.com. Retrieved 2012-08-13. 
  12. ^ Yukhananov, Anna (1 May 2012). "U.S. FDA approves Pfizer/Protalix drug for Gaucher".  
  13. ^ Actelion. FDA Advisory Briefing Book for Miglustat (Ogt 918, Zavesca®) in Niemann-Pick Type C Disease NDA 021-348/S-007 Prepared for the Endocrinologic and Metabolic Drugs Advisory Committee meeting, 1 December 2009
  14. ^ Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J (December 2011). "Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase".  
  15. ^ European Medicines Agency 1 April 2003 Scientific discussion related to approval of Zavesca.
  16. ^ Clinicaltrials.gov Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses Accessed 1 September 2014
  17. ^ Clinicaltrials.gov Miglustat / OGT 918 in the Treatment of Cystic Fibrosis Accessed 1 September 2014
  18. ^ Leonard A et al. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros. 2012 May;11(3):231-6. doi: 10.1016/j.jcf.2011.12.004. Epub 2012 Jan 27. PMID 22281182
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.